Meronia IV 1000 mg

Active substance :  meropenem

Form : Powder for solution for injection or infusion

Dosage :  500 mg per vial Meronia 500 IV  / 1000 mg per vial Meronia 1000 IV

Packaging :

Box with 1  20 ml vial for Meronia 500 IV

Box with 1  20 ml vial for Meronia 1000 IV

Target : Adults and children from 3 months and older

Clinical experience indicates that the product can also be given to younger children

Meronia IV is indicated for the treatment of the following infections in adults and children aged 3 months and older.

• Severe pneumonia, including hospital and ventilator‐associated pneumonia.
• Broncho‐pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra‐abdominal infections
• Intra‐ and post‐partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
• in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
• Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

Unit doses in function of the infection :  500 mg to 1000 mg  to be given each 8 hours

Children below 11 y of age (<50kg)  : 10 to 20 mg/kg , mg  to be given each 8 hours

A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species or very severe infections.

Method of administration :

– Meronia is usually administered as an intravenous infusion over approximately 15 to 30 minutes.

– It is also possible to administer doses of Meronia up to 20 mg/kg as an intravenous bolus over approximately 5 minutes.

There is evidence from clinical experience as well as recent scientific literature of prolonged infusion for up to 3 hours with very good efficacy and less risk of adverse effects.

A solution for bolus injection is prepared by diluting the product in water for injection to a final concentration of 50 mg/ml.

A solution for infusion is prepared by diluting the product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to give a final concentration of 1-20 mg/ml.

The chemical and physical stability of use has been demonstrated for 3 hours up to 25°C or 12 hours under refrigerated conditions (2-8°C).

From a microbiological point of view, unless the risk of bacterial contamination during opening, reconstitution and dilution is eliminated, the product must be used immediately.

If not used immediately, storage times and conditions are the responsibility of the user.